Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2005 2
2007 1
2008 1
2010 3
2011 2
2012 4
2014 3
2015 7
2016 5
2017 3
2018 5
2019 5
2020 5
2021 7
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

47 results
Results by year
Filters applied: . Clear all
Page 1
Super-enhancer-based identification of a BATF3/IL-2R-module reveals vulnerabilities in anaplastic large cell lymphoma.
Liang HC, Costanza M, Prutsch N, Zimmerman MW, Gurnhofer E, Montes-Mojarro IA, Abraham BJ, Prokoph N, Stoiber S, Tangermann S, Lobello C, Oppelt J, Anagnostopoulos I, Hielscher T, Pervez S, Klapper W, Zammarchi F, Silva DA, Garcia KC, Baker D, Janz M, Schleussner N, Fend F, Pospíšilová Š, Janiková A, Wallwitz J, Stoiber D, Simonitsch-Klupp I, Cerroni L, Pileri S, de Leval L, Sibon D, Fataccioli V, Gaulard P, Assaf C, Knörr F, Damm-Welk C, Woessmann W, Turner SD, Look AT, Mathas S, Kenner L, Merkel O. Liang HC, et al. Among authors: merkel o. Nat Commun. 2021 Sep 22;12(1):5577. doi: 10.1038/s41467-021-25379-9. Nat Commun. 2021. PMID: 34552066 Free PMC article.
Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study.
Snijder B, Vladimer GI, Krall N, Miura K, Schmolke AS, Kornauth C, Lopez de la Fuente O, Choi HS, van der Kouwe E, Gültekin S, Kazianka L, Bigenzahn JW, Hoermann G, Prutsch N, Merkel O, Ringler A, Sabler M, Jeryczynski G, Mayerhoefer ME, Simonitsch-Klupp I, Ocko K, Felberbauer F, Müllauer L, Prager GW, Korkmaz B, Kenner L, Sperr WR, Kralovics R, Gisslinger H, Valent P, Kubicek S, Jäger U, Staber PB, Superti-Furga G. Snijder B, et al. Among authors: merkel o. Lancet Haematol. 2017 Dec;4(12):e595-e606. doi: 10.1016/S2352-3026(17)30208-9. Epub 2017 Nov 15. Lancet Haematol. 2017. PMID: 29153976 Free PMC article. Clinical Trial.
Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders.
Kornauth C, Pemovska T, Vladimer GI, Bayer G, Bergmann M, Eder S, Eichner R, Erl M, Esterbauer H, Exner R, Felsleitner-Hauer V, Forte M, Gaiger A, Geissler K, Greinix HT, Gstöttner W, Hacker M, Hartmann BL, Hauswirth AW, Heinemann T, Heintel D, Hoda MA, Hopfinger G, Jaeger U, Kazianka L, Kenner L, Kiesewetter B, Krall N, Krajnik G, Kubicek S, Le T, Lubowitzki S, Mayerhoefer ME, Menschel E, Merkel O, Miura K, Müllauer L, Neumeister P, Noesslinger T, Ocko K, Öhler L, Panny M, Pichler A, Porpaczy E, Prager GW, Raderer M, Ristl R, Ruckser R, Salamon J, Schiefer AI, Schmolke AS, Schwarzinger I, Selzer E, Sillaber C, Skrabs C, Sperr WR, Srndic I, Thalhammer R, Valent P, van der Kouwe E, Vanura K, Vogt S, Waldstein C, Wolf D, Zielinski CC, Zojer N, Simonitsch-Klupp I, Superti-Furga G, Snijder B, Staber PB. Kornauth C, et al. Among authors: merkel o. Cancer Discov. 2022 Feb;12(2):372-387. doi: 10.1158/2159-8290.CD-21-0538. Epub 2021 Oct 11. Cancer Discov. 2022. PMID: 34635570
Personalized medicine aims to match the right drug with the right patient by using specific features of the individual patient's tumor. However, current strategies of personalized therapy matching provide treatment opportunities for less than 10% of patients with cancer. . …
Personalized medicine aims to match the right drug with the right patient by using specific features of the individual patient's tumo …
Lipids and polymers in pharmaceutical technology: Lifelong companions.
Siepmann J, Faham A, Clas SD, Boyd BJ, Jannin V, Bernkop-Schnürch A, Zhao H, Lecommandoux S, Evans JC, Allen C, Merkel OM, Costabile G, Alexander MR, Wildman RD, Roberts CJ, Leroux JC. Siepmann J, et al. Among authors: merkel om. Int J Pharm. 2019 Mar 10;558:128-142. doi: 10.1016/j.ijpharm.2018.12.080. Epub 2019 Jan 9. Int J Pharm. 2019. PMID: 30639218 Free article. Review.
JAK-STAT signaling in cancer: From cytokines to non-coding genome.
Pencik J, Pham HT, Schmoellerl J, Javaheri T, Schlederer M, Culig Z, Merkel O, Moriggl R, Grebien F, Kenner L. Pencik J, et al. Among authors: merkel o. Cytokine. 2016 Nov;87:26-36. doi: 10.1016/j.cyto.2016.06.017. Epub 2016 Jun 24. Cytokine. 2016. PMID: 27349799 Free PMC article. Review.
Novel treatment avenues for peripheral T-cell lymphomas.
Hopfinger G, Griessl R, Sifft E, Taylor N, Kenner L, Greil R, Merkel O. Hopfinger G, et al. Among authors: merkel o. Expert Opin Drug Discov. 2012 Dec;7(12):1149-63. doi: 10.1517/17460441.2012.727392. Epub 2012 Sep 24. Expert Opin Drug Discov. 2012. PMID: 22998641 Review.
INTRODUCTION: Peripheral T-cell lymphomas (PTCLs) and natural killer (NK) or T-cell non-Hodgkin's lymphomas (NHLs) are a rare and heterogeneous class of diseases with generally poor prognosis. ...
INTRODUCTION: Peripheral T-cell lymphomas (PTCLs) and natural killer (NK) or T-cell non-Hodgkin's lymphomas (NHLs) are a rare and het …
Thyroid and androgen receptor signaling are antagonized by μ-Crystallin in prostate cancer.
Aksoy O, Pencik J, Hartenbach M, Moazzami AA, Schlederer M, Balber T, Varady A, Philippe C, Baltzer PA, Mazumder B, Whitchurch JB, Roberts CJ, Haitel A, Herac M, Susani M, Mitterhauser M, Marculescu R, Stangl-Kremser J, Hassler MR, Kramer G, Shariat SF, Turner SD, Tichy B, Oppelt J, Pospisilova S, Hartenbach S, Tangermann S, Egger G, Neubauer HA, Moriggl R, Culig Z, Greiner G, Hoermann G, Hacker M, Heery DM, Merkel O, Kenner L. Aksoy O, et al. Among authors: merkel o. Int J Cancer. 2021 Feb 1;148(3):731-747. doi: 10.1002/ijc.33332. Epub 2020 Oct 31. Int J Cancer. 2021. PMID: 33034050 Free PMC article.
STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma.
Lobello C, Tichy B, Bystry V, Radova L, Filip D, Mraz M, Montes-Mojarro IA, Prokoph N, Larose H, Liang HC, Sharma GG, Mologni L, Belada D, Kamaradova K, Fend F, Gambacorti-Passerini C, Merkel O, Turner SD, Janikova A, Pospisilova S. Lobello C, et al. Among authors: merkel o. Leukemia. 2021 May;35(5):1500-1505. doi: 10.1038/s41375-020-01093-1. Epub 2020 Nov 27. Leukemia. 2021. PMID: 33247178 Free PMC article. No abstract available.
When the guardian sleeps: Reactivation of the p53 pathway in cancer.
Merkel O, Taylor N, Prutsch N, Staber PB, Moriggl R, Turner SD, Kenner L. Merkel O, et al. Mutat Res Rev Mutat Res. 2017 Jul;773:1-13. doi: 10.1016/j.mrrev.2017.02.003. Epub 2017 Feb 17. Mutat Res Rev Mutat Res. 2017. PMID: 28927521 Free article. Review.
Finally, we will also touch on gene therapy and vaccination approaches; the former of which aims to replace mutated TP53 and the latter whose goal is to activate the body's immune system toward mutant p53 expressing cells. Besides the obvious importance of MDM2 and MDMX ex …
Finally, we will also touch on gene therapy and vaccination approaches; the former of which aims to replace mutated TP53 and the latter whos …
47 results